Work

Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment

Year: 2024

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(24)00609-8

Authors: Moshe Levy, David Andorsky, Ghayas Issa, Edward Broun, James Essell, Camille Abboud, Andrea Damon, Amy Starinsky, Islam Sadek, Naseema Parveen, Michael Mauro, Michael Deininger

Institutions: Baylor Scott & White Health, Rocky Mountain Cancer Centers, The University of Texas MD Anderson Cancer Center, Oncology Hematology Care, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center, University of Utah

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401896494

FWCI:

Cites:

Cited by:

Related to: 10